Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Janus Kinase Inhibitors in Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same author

Association of folylpolyglutamate synthase polymorphisms with methotrexate response and toxicity in rheumatoid arthritis: a meta-analysis.

The pharmacogenomics journal·2026
Same author

Indirect comparative efficacy and safety of belimumab vs. anifrolumab in systemic lupus erythematosus and lupus nephritis: a meta-analysis of randomized trials.

Zeitschrift fur Rheumatologie·2025
Same author

Association between miRNA polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis.

Biomarkers in medicine·2025
Same author

Rituximab in Sjögren's disease: reconciling evidence from randomized and observational studies.

Journal of rheumatic diseases·2025
Same author

Comparative efficacy and safety of denosumab biosimilar and originator in postmenopausal osteoporosis: a meta-analysis of randomized controlled trials.

Zeitschrift fur Rheumatologie·2025

Related Experiment Video

Updated: Jan 8, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K

Elevated circulating interleukin-17 levels in systemic sclerosis: a meta-analysis.

Young Ho Lee1, Gwan Gyu Song1

  • 1Division of Rheumatology, Department of Internal Medicine, Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Journal of Rheumatic Diseases
|December 18, 2025
PubMed
Summary

This meta-analysis found that while overall interleukin-17 (IL-17) levels did not differ between systemic sclerosis (SSc) patients and controls, specific subtypes like IL-17A were significantly elevated in SSc, suggesting a role in disease pathogenesis.

Keywords:
CytokinesInflammationInterleukin-17Meta-analysisSystemic sclerosis

More Related Videos

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.4K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

705

Related Experiment Videos

Last Updated: Jan 8, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.4K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

705

Area of Science:

  • Immunology
  • Rheumatology
  • Biochemistry

Background:

  • Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis and vascular abnormalities.
  • Interleukin-17 (IL-17) is a pro-inflammatory cytokine implicated in various autoimmune and inflammatory conditions.

Purpose of the Study:

  • To conduct a meta-analysis evaluating the association between circulating interleukin-17 (IL-17) levels and systemic sclerosis (SSc).
  • To compare IL-17 levels in SSc patients versus healthy controls and analyze specific IL-17 subtypes.

Main Methods:

  • A systematic literature search was performed across MEDLINE, Embase, and Web of Science.
  • Included 16 studies with 1,229 SSc patients and 839 controls, comparing serum/plasma levels of IL-17, IL-17A, IL-17B, IL-17E, and IL-17F.
  • Subgroup analyses were conducted based on ethnicity and disease subtype.

Main Results:

  • Overall circulating IL-17 levels showed no significant difference between SSc patients and controls (SMD=0.260, p=0.825).
  • However, IL-17A, IL-17B, IL-17E, and IL-17F levels were significantly elevated in SSc patients (p<0.05 for all).
  • IL-17A exhibited the most pronounced association (SMD=2.046, p=0.002). No significant difference in IL-17A was found between diffuse and limited SSc.

Conclusions:

  • Specific IL-17 subtypes, particularly IL-17A, IL-17B, IL-17E, and IL-17F, are significantly elevated in systemic sclerosis.
  • These findings suggest that IL-17 cytokines, especially IL-17A, play a crucial role in the pathogenesis of SSc.